GlassScriptPhysician profile
Mohammad A Khan
NPI 1528028032
$5,049.35
in general payments reported to CMS, 2019-2025
23 companies · $821 in 2025
The $821 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,791 · 2020: $325 · 2021: $271 · 2022: $294 · 2023: $253 · 2024: $294 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,297.33 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $554.02 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $393.54 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $328.66 | 2020-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $217.97 | 2021-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.62 | 2020-2025 | Caplyta |
| Abbvie INC. | $152.77 | 2021-2025 | |
| Abiomed | $147.20 | 2020 | |
| Alkermes, INC. | $134.54 | 2019 | |
| Sunovion Pharmaceuticals INC. | $128.75 | 2021-2022 | |
| Corium, LLC | $85.36 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $80.46 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $76.75 | 2019 | |
| Axsome Therapeutics, INC. | $58.14 | 2025 | Auvelity |
| Lundbeck LLC | $55.55 | 2022-2023 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $40.22 | 2025 | Xelstrym, Secuado |
| Tris Pharma INC | $37.62 | 2023 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $24.89 | 2020 | |
| Neurocrine Biosciences, INC. | $21.06 | 2020 | |
| Mimedx Group, INC. | $19.27 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.41 | 2019 | |
| Tactile Systems Technology INC | $12.99 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.